GlassScriptPhysician profile
Joseph C James
NPI 1447310206
$4,495.41
in general payments reported to CMS, 2019-2025
30 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $299 · 2022: $772 · 2023: $1,102 · 2024: $1,254 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,424.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $912.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $367.50 | 2024-2025 | Airsupra, Farxiga |
| Abbott Laboratories | $359.22 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Madrigal Pharmaceuticals | $354.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $353.24 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $298.21 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $189.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $152.76 | 2023-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $148.41 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $145.66 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $124.99 | 2023 | Uzedy |
| Shield Therapeutics INC | $107.45 | 2024 | |
| Gilead Sciences, INC. | $105.30 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $100.38 | 2024 | Voquezna |
| Pfizer INC. | $93.31 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $89.07 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $85.50 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $69.23 | 2022-2025 | Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $67.63 | 2022 | |
| Eisai INC. | $61.12 | 2024 | |
| Glaxosmithkline, LLC. | $57.18 | 2023-2025 | Shingrix, Arexvy |
| Insmed, INC. | $57.16 | 2024 | Arikayce |
| Xeris Pharmaceuticals, INC. | $37.81 | 2024-2025 | Gvoke Hypopen |
| Angiodynamics, INC. | $34.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.47 | 2023 | Jardiance |
| Mannkind Corporation | $21.47 | 2022 | |
| Optinose US, INC. | $20.98 | 2025 | |
| Insulet Corporation | $18.43 | 2025 | Omnipod |
| Ibsa Pharma INC. | $17.50 | 2024 | Licart, Tirosint |
| Ucb, INC. | $14.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.